- Home
- DSGR vs TRVI Comparison
DSGR vs TRVI Comparison
Compare DSGR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSGR | TRVI |
|---|---|---|
| Founded | 1952 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | DSGR | TRVI |
|---|---|---|
| Price | $28.95 | $10.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $41.00 | $20.38 |
| AVG Volume (30 Days) | 62.2K | ★ 1.3M |
| Earning Date | 03-05-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,978,887,000.00 | N/A |
| Revenue This Year | $12.80 | N/A |
| Revenue Next Year | $4.23 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.46 | N/A |
| 52 Week Low | $21.87 | $3.73 |
| 52 Week High | $34.65 | $14.39 |
Technical Indicators
Market Signals| Indicator | DSGR | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 50.04 | 34.14 |
| Support Level | $28.83 | $10.17 |
| Resistance Level | $30.26 | $11.15 |
| Average True Range (ATR) | 0.91 | 0.73 |
| MACD | -0.04 | -0.13 |
| Stochastic Oscillator | 43.98 | 3.52 |
Price Performance
Historical ComparisonAbout DSGR Distribution Solutions Group Inc.
Distribution Solutions Group Inc is an industrial distributor of maintenance and repair supplies. It has three operating segments namely Lawson, TestEquity, and Gexpro Services, of which key revenue is derived from the TestEquity segment. The TestEquity segment is a distributor of test and measurement equipment and solutions, electronic production supplies, and tool kits from its manufacturer partners supporting the technology, aerospace, defense, automotive, electronics, education and medical industries.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.